Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01267266 · ClinicalTrials.gov registry record · Phase 2
Saracatinib in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01267266: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01267266 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01267266, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This randomized phase II clinical trial is studying how well saracatinib works in treating patients with prostate cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Time to progression will be assessed using the Kaplan-Meier method and compared between groups via Wilcoxon rank-sum test.
Interventions
- DRUG saracatinib
- OTHER hydrocortisone/placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Why NCT01267266 stopped before completion
NCT01267266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which saracatinib is the first listed.
NCT01267266 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01267266 about?
NCT01267266 is a clinical study titled "Saracatinib in Treating Patients With Prostate Cancer". This randomized phase II clinical trial is studying how well saracatinib works in treating patients with prostate cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01267266?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2010-12. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01267266?
The interventions under investigation include: saracatinib (DRUG), hydrocortisone/placebo (OTHER).
Who is sponsoring clinical trial NCT01267266?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01267266's enrollment target sits among peer trials
31 1578th of 2000 higher than 419 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia